154 related articles for article (PubMed ID: 20679626)
21. Underuse of anthracyclines in women with HER-2+ advanced breast cancer.
Montemurro F; Rossi V; Nolè F; Redana S; Donadio M; Martinello R; Verri E; Valabrega G; Rocca MC; Jacomuzzi ME; Viale G; Sapino A; Aglietta M
Oncologist; 2010; 15(7):665-72. PubMed ID: 20576644
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
23. Clinical cardiac tolerability of trastuzumab.
Perez EA; Rodeheffer R
J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
[TBL] [Abstract][Full Text] [Related]
24. [Therapy concept: herceptin with anthracyclines].
Untch M
Onkologie; 2002 Dec; 25 Suppl 5():19-21; discussion 21. PubMed ID: 23573616
[No Abstract] [Full Text] [Related]
25. Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?
Bozovic-Spasojevic I; Azim HA; Paesmans M; Suter T; Piccart MJ; de Azambuja E
Lancet Oncol; 2011 Mar; 12(3):209-11. PubMed ID: 21354372
[No Abstract] [Full Text] [Related]
26. Anthracycline cardiotoxicity after breast cancer treatment.
Hershman DL; Shao T
Oncology (Williston Park); 2009 Mar; 23(3):227-34. PubMed ID: 19418823
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
28. Trastuzumab and breast cancer.
Palmieri C; Powles T; Vigushin D
N Engl J Med; 2001 Sep; 345(13):996-7. PubMed ID: 11575297
[No Abstract] [Full Text] [Related]
29. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
Martín M; Esteva FJ; Alba E; Khandheria B; Pérez-Isla L; García-Sáenz JA; Márquez A; Sengupta P; Zamorano J
Oncologist; 2009 Jan; 14(1):1-11. PubMed ID: 19147689
[TBL] [Abstract][Full Text] [Related]
30. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Morris PG; Chen C; Steingart R; Fleisher M; Lin N; Moy B; Come S; Sugarman S; Abbruzzi A; Lehman R; Patil S; Dickler M; McArthur HL; Winer E; Norton L; Hudis CA; Dang CT
Clin Cancer Res; 2011 May; 17(10):3490-9. PubMed ID: 21372222
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab cardio-oncology: lessons learned.
Frankel C
Clin J Oncol Nurs; 2010 Oct; 14(5):630-40. PubMed ID: 20880820
[TBL] [Abstract][Full Text] [Related]
32. Managing cardiotoxicity in anthracycline-treated breast cancers.
Ng R; Green MD
Expert Opin Drug Saf; 2007 May; 6(3):315-21. PubMed ID: 17480180
[TBL] [Abstract][Full Text] [Related]
33. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
34. Implications of excess weight in the cardiotoxicity of anthracyclines and trastuzumab in breast cancer.
Guenancia C; Ladoire S; Ghiringelli F; Rochette L; Vergely C; Cottin Y
Arch Cardiovasc Dis; 2017 Feb; 110(2):69-71. PubMed ID: 28216265
[No Abstract] [Full Text] [Related]
35. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?
Morabito A; Piccirillo MC; De Maio E; Di Maio M; Perrone F
J Clin Oncol; 2009 Sep; 27(27):e123; author reply e124-5. PubMed ID: 19687322
[No Abstract] [Full Text] [Related]
37. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
38. [Cardiac prevention: the oncologic point of view].
Gligorov J; Debourdeau P; Arsovski O; Lotz JP
Bull Cancer; 2004 Nov; 91 Suppl 3():192-200. PubMed ID: 15899627
[TBL] [Abstract][Full Text] [Related]
39. [Cardiac dysfunction induced by trastuzumab].
Campone M; Bourbouloux E; Fumoleau P
Bull Cancer; 2004 Nov; 91 Suppl 3():166-73. PubMed ID: 15899624
[TBL] [Abstract][Full Text] [Related]
40. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
Suter TM; Cook-Bruns N; Barton C
Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]